A precision medicine approach to defining the impact of doxorubicin on the bioenergetic-metabolite interactome in human platelets.

ABSTRACT: Non-invasive measures of the response of individual patients to cancer therapeutics is an emerging strategy in precision medicine. Platelets offer a potential dynamic marker for metabolism and bioenergetic responses in individual patients since they have active glycolysis and mitochondrial oxidative phosphorylation and can be easily isolated from a small blood sample. We have recently shown how the bioenergetic-metabolite interactome can be defined in platelets isolated from human subjects by measuring metabolites and bioenergetics in the same sample. In the present study, we used a model system to assess test the hypothesis that this interactome is modified by xenobiotics using exposure to the anti-cancer drug doxorubicin (Dox) in individual donors. We found that unsupervised analysis of

SUBMITTER: Smith MR 

PROVIDER: S-EPMC6812033 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature